[144] Adaptive Biotechnologies Corp SEC Filing
Rhea-AI Filing Summary
ADPT submitted a Form 144 notice reporting proposed sales of common stock.
The filing lists a proposed sale of 5,000 common shares tied to previously exercised stock options dated 01/25/2022. The excerpt also discloses recent 10b5-1 sales by Susan Bobulsky: 11,000 shares on 06/04/2026 for $198,000 and 5,000 shares on 06/11/2026 for $95,000.
Positive
- None.
Negative
- None.
Insights
TL;DR: Routine Rule 144 notice and disclosed 10b5-1 sales; no new proceeds treatment specified.
The filing lists a proposed sale of 5,000 common shares described as issuable from previously exercised stock options dated 01/25/2022. It also records two recent 10b5-1 dispositions by Susan Bobulsky on 06/04/2026 and 06/11/2026, with aggregate proceeds of $293,000.
Timing and exact cash‑flow treatment for the proposed sale are not further detailed in the provided excerpt; regulatory mechanics (holding periods or resale conditions) are governed by Rule 144 and any plan language referenced on the face of the notice.
TL;DR: Disclosed transactions are routine insider sales under a trading plan and a Rule 144 notice.
The excerpt shows two executed 10b5-1 sales totaling $293,000 and a listed proposed sale of 5,000 shares tied to prior option exercises. The figures are explicit: $198,000 (11,000 shares) and $95,000 (5,000 shares).
These are transactional disclosures rather than operational or financial results; their investor significance depends on broader ownership context, which is not included in the provided excerpt.